Search by Drug Name or NDC
NDC 00409-2026-01 Docetaxel 10 mg/mL Details
Docetaxel 10 mg/mL
Docetaxel is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Hospira, Inc.. The primary component is DOCETAXEL ANHYDROUS.
MedlinePlus Drug Summary
Docetaxel injection is used alone or in combination with other medications to treat certain types of breast, lung, prostate, stomach, and head and neck cancers. Docetaxel injection is in a class of medications called taxanes. It works by stopping the growth and spread of cancer cells.
Related Packages: 00409-2026-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Docetaxel Injection
Product Information
| NDC | 00409-2026 |
|---|---|
| Product ID | 0409-2026_ec1cf311-020a-4a35-9a70-954b012d804e |
| Associated GPIs | 21500005002030 |
| GCN Sequence Number | 067168 |
| GCN Sequence Number Description | docetaxel VIAL 20 MG/2 ML INTRAVEN |
| HIC3 | V1F |
| HIC3 Description | ANTINEOPLASTICS,MISCELLANEOUS |
| GCN | 29663 |
| HICL Sequence Number | 010280 |
| HICL Sequence Number Description | DOCETAXEL |
| Brand/Generic | Generic |
| Proprietary Name | Docetaxel |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | DOCETAXEL ANHYDROUS |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 10 |
| Active Ingredient Units | mg/mL |
| Substance Name | DOCETAXEL ANHYDROUS |
| Labeler Name | Hospira, Inc. |
| Pharmaceutical Class | Microtubule Inhibition [PE], Microtubule Inhibitor [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA022234 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00409-2026-01 (00409202601)
| NDC Package Code | 0409-2026-01 |
|---|---|
| Billing NDC | 00409202601 |
| Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (0409-2026-01) / 2 mL in 1 VIAL, SINGLE-DOSE |
| Marketing Start Date | 2022-01-10 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |